Canada is signing deals with pharmaceutical giant Pfizer and U.S.-based biotech firm Moderna to procure millions of doses of their experimental COVID-19 vaccines.
OTTAWA — Canada is negotiating deals with pharmaceutical giant Pfizer and U.S.-based biotech firm Moderna to secure millions of doses of their experimental COVID-19 vaccines, in case either is approved for wide-scale use.But Procurement Minister Anita Anand won't say yet how much Canada is spending
Both Pfizer and Moderna began Phase 3 clinical trials of their vaccine candidates in the last week, large-scale tests to determine how well the vaccines work. Both of these vaccines use something called messenger RNA to try to provoke an immune response to COVID-19.
They are among about two dozen COVID-19 vaccine candidates in clinical trials around the world. Dozens more are in earlier stages of development.
Both Pfizer and Moderna are part of the United States government's Operation Warp Speed program to facilitate the development and production of COVID-19 vaccines quickly.
Pfizer said July 22 that it has a US$1.95-billion agreement to supply 100 million doses to the U.S. government, with an option for 500 million more.
Moderna CEO Stephane Bancel said in a conference call Wednesday that small amounts of Moderna's vaccine have been priced between US$32 and US$37 a dose, but that the price would be lower for big orders.
Last month both Pfizer and Moderna reported positive results from smaller trials. Moderna's vaccine was tested on 45 healthy adults between 18 and 55 years old in a Phase 1 trial in May and June, and reported a strong immune response in all people, with mild or moderate side effects such as fatigue, fever and body aches.
Toronto, Ont. ( @YahooCanadaNews )
Canada is signing deals with pharmaceutical giant Pfizer and U.S.-based biotech firm Moderna to procure millions of… twitter.com/i/web/status/1…